StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck adempas (riociguat — direct Merck territory sales) — Worldwide reported growth YoY (%) (%)

Form 8-K Table 3 / 3a / 3b Product Sales

QuarterlyAnnual
Latest, Q2 2026
-2.0%
Period ended Jun 30, 2026
Change on a year earlier
-12.0 pts
10.0% in Q2 2025
History
31 quarters
Since Q4 2017
Sources
31
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdempas (riociguat — direct Merck territory sales) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-2.0%-12.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202514.0%+3.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202514.0%–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202510.0%-1.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q4 2024Dec 31, 202411.0%-4.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2024Jun 30, 202411.0%+8.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202418.0%+21.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202315.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202315.0%+20.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 20233.0%+17.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 2023-3.0%-14.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 2022-5.0%-12.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 2022-14.0%-43.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202211.0%+13.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202119.0%+26.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 20217.0%+12.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗

Cite this data

StockData. (2026). Merck Adempas (riociguat — direct Merck territory sales) — Worldwide reported growth YoY (%) (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_adempas_direct_ww_nom_yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.